Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 199

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 8
Chunk 199
---
 2024 – The increase in total research and development expenses of $18.7 million for the six months ended June 30, 2025 compared to the six months ended June 30, 2024 was due to a $11.9 million increase in our direct expenses and a $6.8 million increase in our indirect expenses. The increase in direct expenses was primarily due to in-process research and development as a result of the $10.0 million milestone payment associated with the agreement with Alnylam discussed above under Overview, and an increase in tebapivat costs due to increased costs associated with clinical trials of tebapivat in patients with SCD and LR MDS. These increases were partially offset by a decrease in PYRUKYND® costs due to lower process development expenses, lower costs associated with the phase 3 ACTIVATE-Kids and ACTIVATE-KidsT trials, and lower costs associated with the phase 3 ENERGIZE and ENERGIZE-T trials, partially offset by increased professional expenses.  The increase in our indirect expenses was primarily due to an increase in compensation and related expenses, driven principally by workforce-related expenses.

Other Income and ExpenseThree Months Ended June 30,Six Months Ended June 30,(In thousands)2025202420252024Interest income, net$14,513 $8,120 $30,600 $17,009 Other income, net523 1,579 1,776 3,213 

Other Income and Expense - Three Months Ended June 30, 2025 vs. Three Months Ended June 30, 2024 –  The increase in interest income, net in the three months ended June 30, 2025 compared to the three months ended June 30, 2024 was primarily attributable to increased return on our investments and an increased investment balance.

Other Income and Expense - Six Months Ended June 30, 2025 vs. Six Months Ended June 30, 2024 –  The increase in interest income, net in the six months ended June 30, 2025 compared to the six months ended June 30, 2024 was primarily attributable to increased return on our investments and an increased investment balance. 

Net LossThree Months Ended June 30,Six Months Ended June 30,(In thousands)2025202420252024Net loss$(112,020)$(96,118)$(201,309)$(177,